FDA Lifts Clinical Hold on Arbutus's AB-101 Oral PD-L1 Inhibitor IND
ABUS sits 21% above its 52-week low of $3.5.
Summary
The FDA lifted the clinical hold on Arbutus's IND for AB-101, an oral PD-L1 inhibitor for chronic hepatitis B, allowing U.S. clinical development to resume. Arbutus says it is still evaluating next steps, with no new trial or timeline disclosed.
Key Events · Product Development and Regulatory · ABUS
-
FDA Lifts AB-101 Clinical Hold
On October 22, 2026, the FDA notified Arbutus that the clinical hold on the IND for AB-101, its oral PD-L1 inhibitor, has been removed and the company may conduct additional U.S. clinical development.
-
Next Steps Still Undecided
Arbutus said it is 'evaluating next steps' for AB-101; no new trial design, start date, or budget was disclosed.
-
Early Phase 1 Data Only
The completed Phase 1a/1b trial (AB-101-001) showed AB-101 was generally well-tolerated with high receptor occupancy in seven chronic HBV patients and hepatitis B surface antigen decline in two patients at the 30mg dose.
-
Cash Position Already Fortified
The regulatory news follows the previously disclosed $178.4M Moderna settlement receipt and the completed $230M tender offer that repurchased 46M shares at $5.00.
Analysis · ABUS · Life Sciences
The FDA has removed the clinical hold on AB-101, freeing Arbutus to resume U.S. clinical development of its oral PD-L1 inhibitor. That reopens a second pipeline asset alongside imdusiran, but the release is thin on specifics: no new trial is scheduled, no timeline is given, and management says only that it is 'evaluating next steps.' The prior Phase 1a/1b data showed the drug was generally well-tolerated with high receptor occupancy in seven chronic HBV patients and surface antigen decline in two at the 30mg dose — early, small numbers that still need confirmation in larger trials. With the balance sheet already bolstered by the $178.4M Moderna settlement and the $230M tender offer complete, this is a pipeline de-risking event rather than a financing one.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1560 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $828.1M. The 52-week trading range was $3.50 to $5.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.